MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1644529

Медицинская библиотека · Frontiers in immunology · 2025

GlyT1 inhibition by ALX-5407 attenuates allograft rejection through suppression of Th1 cell differentiation.

Zhang Xiaohan, Zhang Weiqi, Wei Jianghao, Jin Shuai, Wang Zhen, Wang Hui, Feng Gang, Zhao Jie

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Transplant rejection driven by Th1 cell-mediated immune responses remains a critical challenge. This study aimed to investigate the role of glycine transporter 1 (GlyT1/SLC6A9) in Th1 differentiation and evaluate the therapeutic potential of its inhibitor, ALX-5407, in attenuating allograft rejection.

METHODS

RNA sequencing, flow cytometry, and qRT-PCR were employed to analyze GlyT1 expression in Th1-polarized CD4+T cells. ALX-5407 (0.5-500 nM) was tested in vitro under Th1-polarizing conditions. A murine skin allograft model (BALB/c to C57BL/6) was established to assess graft survival and immune responses. Combination therapy with rapamycin and ALX-5407 was evaluated through histopathology, immunofluorescence, and splenocyte profiling. Mechanistic insights were derived from RNA-seq, KEGG/GO enrichment, and Western blotting.

RESULTS

GlyT1 expression was significantly upregulated in Th1 cells and rejection cohorts. ALX-5407 suppressed Th1 differentiation, reducing IFN-γ+CD4+T cells proportions (p < 0.05) and activation markers (CD25, CD69), while inducing apoptosis via caspase-3 activation and BCL-2 downregulation. Although ALX-5407 monotherapy failed to prolong graft survival, combination with rapamycin synergistically enhanced efficacy (p = 0.018), reduced inflammatory infiltration, and attenuated splenic Th1 polarization. Mechanistically, ALX-5407 inhibited MAPK signaling but activated the PI3K-AKT-mTOR pathway, which rapamycin counteracted to amplify suppression.

CONCLUSIONS

GlyT1 serves as a metabolic checkpoint in Th1 differentiation, and its inhibition by ALX-5407 attenuates allograft rejection through dual suppression of Th1 function and apoptosis induction. Synergy with rapamycin highlights a novel combinatorial strategy to mitigate rejection with reduced toxicity. These findings position GlyT1 targeting as a promising approach for clinical translation in transplantation immunotherapy.

Для цитирования: Zhang Xiaohan, Zhang Weiqi, Wei Jianghao, Jin Shuai, Wang Zhen, Wang Hui, Feng Gang, Zhao Jie. GlyT1 inhibition by ALX-5407 attenuates allograft rejection through suppression of Th1 cell differentiation.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1644529.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.